Gemcitabine doublets in advanced pancreatic cancer: Should we move on?

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 327-329

  Rocha Lima, Caio Max Sao Pedro ^a   Flores, Aurea Maria ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BILE DUCT CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EDITORIAL; HEAD AND NECK CANCER; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; METHODOLOGY; NOTE; PANCREAS TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644838236     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8315     Document Type: Editorial

References (31)

1. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
2. Glimelius B, Hoffman K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600, 1996
3. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
4. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15, 1996 (suppl 10)
5. Grunewald R, Kantarjian H, Keating MJ, et al: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
6. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
7. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
8. Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592, 1999
9. Berlin JD, Adak S, Vaughn DJ, et al: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology 58:215-218, 2000
10. Rocha Lima CM, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191, 2002
11. Brodowicz T, Wolfram RM, Kostler WJ, et al: Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11:623-628, 2000
12. Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569-577, 2001
13. Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512-1518, 2002
14. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
15. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:776-3783, 2004
16. Oettle H, Richards D, Ramanathan RK, et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639-1645, 2005
17. O'Reilly M, Abou-Alfa G, Letourneau R, et al: A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 22:314s, 2004 (suppl 14; abstr 4006)
18. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002
19. Heinemann V, Quietzsch D, Gieseler F, et al: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 22:250, 2003 (abstr 1003)
20. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
21. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79, 1995 (suppl 11)
22. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al: Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 2:521-530, 1996
23. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, et al: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A:2335-2340, 1995
24. Faivre S, Raymond E, Woynarowski JM, et al: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123, 1999
25. Ko AH, Dito E, Shillinger B, et al: A phase II study of gemcitabine at fixed dose rate infusion in combination with low dose cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24:379-385, 2006
26. Vermorken JB, Guastalla JP, Hatty SR, et al: Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer 76:1489-1493, 1997
27. Van Cutsem E, Van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004
28. Bramhall SR, Schulz J, Nemunaitis J, et al: A double blind placebo controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
29. Kindler HL, Friberg G, Stadler WM, et al: Bevacizumab (B) plus gemcitabine (G) in patients with advanced pancreatic cancer: Updated results of a multi-center trial. J Clin Oncol 22:315s, 2004 (suppl 14; abstr 4009)
30. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 22:2610-2616, 2004
31. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). Proc 2005 Gastrointestinal Cancers Symposium, Orlando, FL, January 27-29, 2005 (abstr 77)